EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Turkish Journal of Biochemistry-Turk Biyokimya Dergisi, published by WALTER DE GRUYTER GMBH, is a pivotal open-access journal in the field of biochemistry that serves as a forum for innovative research and scholarly discourse. Since its inception in 2009 and transitioning to open access in 2015, this journal has gained recognition within the scientific community, reflecting a commitment to advancing knowledge in biochemistry and related medical sciences. With a diverse scope that encompasses molecular biology, clinical biochemistry, and the broader arena of biochemical studies, Turkish Journal of Biochemistry offers researchers, professionals, and students access to impactful studies and current developments. Although currently positioned in the lower quartiles in specific categories, the journal aims to enhance its visibility and engagement as it converges towards a promising future, fostering collaboration and knowledge exchange among biochemists across Turkey and around the globe. This journal is vital for anyone seeking to stay abreast of emerging trends and research findings in biochemistry.

Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

Biomedicines, published by MDPI, is a prestigious open-access journal dedicated to the rapidly evolving fields of biochemistry, genetics, and molecular biology, as well as broader aspects of medicine. Since its inception in 2013, Biomedicines has established itself as a leading platform for researchers, practitioners, and students to disseminate high-quality research and innovative findings, reflected in its impressive Q1 ranking in both the Biochemistry, Genetics and Molecular Biology and Medicine categories. With its commitment to accessibility and impactful scholarship, the journal has quickly garnered an international readership, positioning itself as a vital resource in advancing scientific knowledge and fostering collaboration in the biomedical community. Operating from its headquarters in Basel, Switzerland, Biomedicines continues to thrive with features such as rigorous peer review and a fast publication process, making it an essential journal for those looking to contribute to and stay updated in their respective fields.

ACTA BIOCHIMICA POLONICA (ISSN: 0001-527X, E-ISSN: 1734-154X) is a distinguished journal published by the ACTA BIOCHIMICA POLONICA in Poland, with a rich history dating back to 1955. As a prominent platform for disseminating research, it currently holds a Category Quartile of Q3 in the fields of Biochemistry, Genetics, and Molecular Biology, reflecting its commitment to advancing knowledge in these critical areas. This journal is indexed in Scopus, ranking 124 out of 221, placing it in the 44th percentile among general biochemistry, genetics, and molecular biology journals. Although it does not operate under an open-access model, ACTA BIOCHIMICA POLONICA remains a vital resource for researchers, professionals, and students seeking to delve into the latest developments and discoveries in biochemistry and molecular biology. Its strategic focus on contemporary topics ensures that it plays an essential role in shaping future scientific inquiries and fostering collaboration across various disciplines.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

Biochemistry and Biophysics Reports, published by Elsevier, serves as a vital platform for the dissemination of innovative research in the fields of biochemistry, biophysics, cell biology, and molecular biology. With an Open Access model initiated in 2015, this journal aims to facilitate the unimpeded sharing of knowledge, allowing researchers, professionals, and students free access to significant findings and developments. The journal has established a presence in the academic community, currently holding a Q3 ranking in Biochemistry, Q2 in Biophysics, alongside its Q3 standings in both Cell Biology and Molecular Biology categories for 2023. These metrics underscore its commitment to quality and relevance, garnering attention with Scopus ranks reflecting its emerging influence. Located in the Netherlands, Biochemistry and Biophysics Reports continues to foster dialogue and collaboration among the scientific community through high-quality research outputs, contributing to advancements in understanding the intricate biochemical processes and biophysical principles that underpin life sciences.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.